Recurrent Atrial Fibrillation

Atrial Fibrillation Clinical Trial

— Recurrent AF  

Official title:

Recurrent Atrial Fibrillation

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02898545
• Other study ID #: 2015-2478
• Status: Completed
• Phase: N/A
• First received: September 8, 2016
• Last updated: July 28, 2017
• Start date: September 2016
• Est. completion date: July 20, 2017

Study information

• Verified date: July 2017
• Source: University of Cincinnati
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will evaluate the recurrence rates of atrial fibrillation that develops in the hospital following non cardiac procedures or surgeries or acute medical illnesses.

Description:

Eligible individuals with no previous history of atrial fibrillation or flutter who develop a limited episode of atrial fibrillation during a hospital stay for an acute medical illness or non-cardiothoracic surgery or procedure. Patients will be monitored for a period of 1 month using Medtronic SEEQ monitors for recurrence. Subjects will self assign to wear the SEEQ monitor or standard of care. Individuals with implanted cardiac devices capable of detecting atrial fibrillation will also be included.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1
• Est. completion date: July 20, 2017
• Est. primary completion date: July 20, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Development of atrial fibrillation or flutter during a hospital stay following a non-cardiac procedure or acute medical illness

• CHADS2VASc score of 2 or more

Exclusion Criteria:

• Prior history of atrial fibrillation of flutter

• Requiring ventilator support or in shock

• Acute decompensated heart failure or EF =/< 40%

• Greater than mild valvular heart disease

• Other structural heart disease such as more than mild LVH, constrictive or restrictive cardiomyopathy

• Hyperthyroidism uncontrolled at the time of diagnosis if known

• Pulmonary embolism that requires thrombolysis or resulted in shock

• Use of antiarrhythmic drugs (class I or III) at the time of discharge

• Cardiothoracic surgery in the last 6 months

Related Conditions & MeSH terms

• Atrial Fibrillation

Intervention

Device:
• SEEQ monitor
An external cardiac rhythm monitor

Locations

Country	Name	City	State
United States	University of Cincinnati Medical Center	Cincinnati	Ohio

Sponsors (1)

Lead Sponsor	Collaborator
University of Cincinnati

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Recurrence of atrial fibrillation	The rate of recurrence of atrial fibrillation will be compared to the recurrence noted in the standard of care arm.	28 days